J Korean Med Sci.  2024 Oct;39(41):e270. 10.3346/jkms.2024.39.e270.

Patient-Reported Adverse Events Among Elderly Patients Receiving Novel Oral COVID-19 Antivirals: A Nationwide Sampled Survey in Korea

• Jung H
• Park JY
• Yoon D
• Kang DY
• Jung J
• Kim JH
• Shin JY

• KMID: 2560596
• DOI: http://doi.org/10.3346/jkms.2024.39.e270

Abstract

Background
There is a dearth of research on the factors linked with adverse events (AEs) associated with nirmatrelvir/ritonavir (NMVr) and molnupiravir (MOL), particularly in the elderly. Therefore, this study aimed to investigate self-reported AEs and identify factors associated with the occurrence of AEs following NMVr or MOL treatment among survey participants aged 60 years or older in South Korea.
Methods
This nationwide survey was conducted through in-person interviews using structured questionnaires, from July 24 to August 31, 2023. Eligible participants included individuals aged 60 years or older who had been diagnosed with coronavirus disease 2019 (COVID-19) and received NMVr or MOL. The study outcomes included self-reported demographic, lifestyle, and health characteristics associated with the occurrence of AEs. Multivariate logistic regression analysis was used to estimate the adjusted odds ratio (aOR) and 95% confidence interval (CI) of each characteristic in participants with and without AEs.
Results
Of the 520 participants, 123 (23.7%) experienced at least one AE with oral COVID-19 treatment: 21.0% (96/458) for NMVr and 43.5% (27/62) for MOL. None of the participants reported any serious AEs. Increased odds of AE occurrence were observed in participants treated with MOL compared to those treated with NMVr (aOR, 3.05; 95% CI, 1.67–5.57), a history of two or more compared to one COVID-19 diagnosis (1.93; 1.03–3.62), and selfreported health status as “Unhealthy” compared to “Healthy” (2.65; 1.31–5.36).
Conclusion
No AEs required further evaluation to change treatment strategies in elderly patients on NMVr or MOL. Several factors, including the use of MOL, history of COVID-19, and reported health status, were associated with an increased incidence of AEs. Both treatments may still be useful choices for patients with non-severe COVID-19 aged 60 years or older. However, close monitoring of unidentified potential harm and further investigation of the factors associated with the occurrence of AEs are needed.

Keyword

COVID-19; Drug-related Side Effects and Adverse Reactions; Nirmatrelvir and Ritonavir Drug Combination; Molnupiravir; Risk Factors; Survey and Questionnaires; Korea

Reference

1. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. Updated 2023. Accessed January 15, 2024. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic .

2. Ryu BY, Shin EJ, Kim NY, Kim DH, Lee HJ, Kim A, et al. Severity of COVID-19 associated with SARS-CoV-2 variants circulating in the Republic of Korea. Public Health Wkly Rep. 2022; 15(47):2873–2883.

3. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022; 327(6):583–584. PMID: 34967859.

4. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022; 399(10323):437–446. PMID: 35065011.

5. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA. 2022; 327(13):1286–1288. PMID: 35175280.

6. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022; 386(6):509–520. PMID: 34914868.

7. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022; 386(15):1397–1408. PMID: 35172054.

8. US Food & Drug Administration. Emergency use authorization for Lagevrio 2021. Updated 2023. Accessed December 20, 2023. https://www.fda.gov/media/155054/download .

9. US Food & Drug Administration. Emergency use authorization for Paxlovid. 2021. Updated 2023. Accessed December 20, 2023. https://www.fda.gov/media/155050/download .

10. Ministry of Food and Drug Safety (KR). Approval-emergency authorization for Lagevrio. Updated 2022. Accessed February 20, 2024. https://nedrug.mfds.go.kr/bbs/119/222/ .

11. Ministry of Food and Drug Safety (KR). Approval-emergency authorization for Paxlovid. Updated 2021. Accessed January 20, 2024. https://nedrug.mfds.go.kr/bbs/119/133/ .

12. Ministry of Food and Drug Safety (KR). Drug information search for Paxlovid. Updated 2023. Accessed January 15, 2024. https://nedrug.mfds.go.kr/searchDrug?sort=&sortOrder=false&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemName=&itemEngName=paxlovid&entpName=&entpEngName=&ingrName1=&ingrName2=&ingrName3=&ingrEngName=&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&sClassNo=&narcoticKindCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&searchConEe=AND&eeDocData=&searchConUd=AND&udDocData=&searchConNb=AND&nbDocData=&startPermitDate=&endPermitDate .

13. Shinozaki S, Watanabe A, Kimata M, Miyazaki M, Maekawa S. Safety and effectiveness of molnupiravir in Japanese patients with COVID-19: final report of post-marketing surveillance in Japan. Infect Dis Ther. 2024; 13(1):189–205. PMID: 38233606.

14. Cvancara DJ, Baertsch HC, Lehmann AE, Humphreys IM, Farrell NF, Marshall TB, et al. Postmarketing reporting of paxlovid-related dysgeusia: a real-world pharmacovigilance study. Otolaryngol Head Neck Surg. 2023; 169(1):55–61. PMID: 36821807.

15. Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse events associated with nirmatrelvir/ritonavir: a pharmacovigilance analysis based on FAERS. Pharmaceuticals (Basel). 2022; 15(12):1455. PMID: 36558906.

16. Zhuang W, Xu J, Wu Y, Yang J, Lin X, Liao Y, et al. Post-marketing safety concerns with nirmatrelvir: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Br J Clin Pharmacol. 2023; 89(9):2830–2842. PMID: 37170890.

17. Mazzitelli M, Mengato D, Sasset L, Ferrari A, Gardin S, Scaglione V, et al. Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study. Viruses. 2023; 15(2):384. PMID: 36851598.

18. Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, et al. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience. Infect Dis Ther. 2023; 12(1):257–271. PMID: 36441485.

19. Yip TC, Lui GC, Lai MS, Wong VW, Tse YK, Ma BH, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis. 2023; 76(3):e26–e33. PMID: 36031408.

20. Park JJ, Kim H, Kim YK, Lee SS, Jung E, Lee JS, et al. Effectiveness and adverse events of nirmatrelvir/ritonavir versus molnupiravir for COVID-19 in outpatient setting: multicenter prospective observational study. J Korean Med Sci. 2023; 38(42):e347. PMID: 37904658.

21. Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge. N Engl J Med. 2022; 387(9):790–798. PMID: 36001529.

22. Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022; 22(12):1681–1693. PMID: 36029795.

23. Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023; 23(6):696–705. PMID: 36780912.

24. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023; 76(3):e342–e349. PMID: 35653428.

25. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022; 112(6):1191–1200. PMID: 35567754.

26. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis. 2023; 76(1):165–171. PMID: 35245942.

27. Caronia L, Xi R, Margolskee RF, Jiang P. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir. Biochem Biophys Res Commun. 2023; 682:138–140. PMID: 37806252.

28. Ruenjaiman V, Hirankarn N, Palaga T. Innate immunity in COVID-19: drivers of pathogenesis and potential therapeutic targets. Asian Pac J Allergy Immunol. 2021; 39(2):69–77. PMID: 34174806.